Reported Earlier, HUTCHMED Announces Phase III ESLIM-02 Trial Success For Sovleplenib Expanding Immunology And Hematology Pipeline

Benzinga · 4d ago

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —